Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
SNDX
#1702
Syndax Pharmaceuticals, Inc.
21.7
1
+6.89%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
+6.89%
Changement Mensuel
+1.92%
Evolution sur 6 mois
+32.54%
Changement Annuel
+43.02%
Clôture Précédente
20.3
1
Open
21.7
1
Bid
Ask
Low
21.7
1
High
21.7
1
Volume
124
Marchés
Actions des Marchés US
Soins de Santé
SNDX
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
85.57 M
86.02 M
86.05 M
86.14 M
86.91 M
88.2 M
—
Valuation ratios
Enterprise value
—
983.16 M
903.1 M
698.08 M
1.22 B
1.72 B
4.54 B
Price to earnings ratio
-5.27
-3.55
-3.19
-2.41
-4.27
-6.39
-16.26
Price to sales ratio
102.62
47.8
24.09
10.3
11.9
—
—
Price to cash flow ratio
-6.13
-4.12
-3.67
-2.66
-4.26
5.64
-4.96
Price to book ratio
0.84
3.93
0.81
0.78
1.71
28.16
31.45
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.2
0.13
0.13
0.12
0.11
0.13
0.49
Return on equity %
0.23
0.33
0.39
0.46
0.53
1.05
2.43
Return on invested capital %
678.91
—
183.19
177.62
182.98
248.51
792.31
Gross margin %
100
100
100
100
100
100
400
Operating margin %
716.62
1 254.75
417.91
182.71
125.19
91.34
817.14
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
673.01
1 226.16
423.34
189.28
132.36
99.32
844.3
Liquidity ratios
Quick ratio
—
5.82
5.75
4.55
4.42
4.12
18.85
Current ratio
6.99
5.82
5.8
4.71
4.64
4.4
19.55
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.03
0.01
0.03
0.06
0.08
0.13
0.3
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
0.46
-0.01
-0.01
-0.01
-0.01
-0.04
Long term debt to total equity ratio
—
1.15
-0.03
-0.04
-0.05
-0.09
-0.21
Per share metrics
Operating cash flow per share
0.73
0.67
1.1
1.02
0.81
0.8
3.74
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
4.56
6.69
5.94
5.27
5.03
4.55
20.8
Net current asset value per share
4.86
7.04
6.37
6.16
6.12
6.1
24.74
Tangible book value per share
4.29
3.37
2.5
1.82
1.33
0.75
6.4
Working capital per share
4.16
5.83
5.27
4.85
4.8
4.71
19.63
Book value per share
4.29
3.37
2.5
1.82
1.33
0.75
6.4
Nouvelles
Stifel上调Syndax Pharmaceuticals目标价,看好药品销售前景
Stifel raises Syndax Pharmaceuticals stock price target on drug sales
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call Transcript
Syndax 2025年第四季度业绩:收入激增50%,盈利路径明确
Syndax Q4 2025 slides: revenue surges 50%, profitability path outlined
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates
Syndax Pharmaceuticals Q4 每股收益 逊于预期, 营收 超出预期
Syndax Pharmaceuticals earnings missed by $0.19, revenue topped estimates
Syndax面临财报考验,抗癌药物上市提速
Syndax faces earnings test as cancer drug launches accelerate
新达制药参加古根海姆峰会:强劲增长与战略扩张
Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026 (NASDAQ:SNDX)